Imperial College London


Faculty of MedicineNational Heart & Lung Institute

Professor of Cardiac Pharmacology



+44 (0)20 7594 3009sian.harding Website




435ICTEM buildingHammersmith Campus





Sian Harding is Professor of Cardiac Pharmacology at the National Heart and Lung Institute, Imperial College, as well as Institute Lead for Women for Athena Swan, and a co-investigator within the UKRMP Immunomodulation Hub.

She obtained her Ph.D. in Pharmacology from King's College, London in 1981, and since then the primary focus of her work has been cardiomyocyte function in the failing heart. This has extended to gene therapy to modulate cardiomyocyte function, and she is Scientific PI for the UK's first clinical trial on myocardial gene therapy. More recently the scope has extended to the characterisation of cardiomyocytes derived from embryonic stem cells, and their use in cardiac repair, tissue engineering and drug discovery.

Professor Harding is Past-President of the European Section of the International Society for Heart Research and Fellow of the AHA, ESC and ISHR. She sits on the Nuffield Council on Bioethics and the Scientific Advisory Board of the PPP "Stem Cells for Safer Medicines".

Professor Harding delivered her Inaugural Lecture, entitled 'Reviving the Failing Heart: one cell at a time', on 3 April 2007.  The abstract and other details of the lecture can be found here.



YouTube placeholder



Hasham MG, Baxan N, Stuckey D, et al., Systemic autoimmunity induced by Toll-like receptor 7/8 agonist Resiquimod causes myocarditis and dilated cardiomyopathy: a new model of autoimmune heart disease, Disease Models & Mechanisms

Bagdadi AV, Safari M, Dubey P, et al., 2016, Poly(3-hydroxyoctanoate), a promising new material for cardiac tissue engineering., J Tissue Eng Regen Med


Elder JM, O'Gara P, Sanchez-Alonso JL, et al., 2016, Doxorubicin modulates the real-time oxygen consumption rate of freshly isolated adult rat and human ventricular cardiomyocytes, Frontiers in CardioVascular Biology Meeting (FCVB), OXFORD UNIV PRESS, Pages:S111-S111, ISSN:0008-6363

Foldes G, Hellen N, Vittay O, et al., 2016, Hippo signalling modulates survival of human induced pluripotent stem cell-derived cardiomyocytes, Frontiers in CardioVascular Biology Meeting (FCVB), OXFORD UNIV PRESS, Pages:S92-S93, ISSN:0008-6363

Gara E, Kiraly SZ, Kiszler G, et al., 2016, FOXO1A modifies arterial and venous endothelial development from human pluripotent stem cells; they establish 3D vascular structures in vitro and quantifiable vascular networks in vivo, Congress of the European-Society-of-Cardiology (ESC), OXFORD UNIV PRESS, Pages:703-703, ISSN:0195-668X

More Publications